Regulatory & medical writing for pharma and medtech submissions (CSR, CTD/eCTD, MDR technical documentation)

Regulatory submissions run to thousands of pages: clinical study reports (CSR), CTD/eCTD modules, protocols, safety reports and, for devices, MDR technical documentation with clinical evaluation reports. Medical writers assemble them by hand from statistical outputs and source documents. GenAI produces first drafts that are tied to their source tables, checks consistency across documents and leaves scientific judgement and sign-off to qualified humans under GxP controls. Vendors and sponsors report shorter drafting cycles; published figures vary and should be verified on your own documents.

Problem & value

• Today: writers copy numbers from tables into templates (ICH E3 for CSRs, CTD M4 for dossiers, MDR Annex II/III for devices), then reviewers hunt for inconsistencies between protocol, SAP, CSR, Module 2 summaries and labelling. Rework after late data changes is a major cost and timeline risk.
• AI value: auto-drafting of data-driven sections (disposition, demographics, efficacy and safety text from TLFs), patient narratives, lay summaries, literature screening for clinical evaluation, and automated cross-checks of numbers, abbreviations and terminology.
• Evidence: Novo Nordisk has described its NovoScribe platform (built on Claude) for CSR drafting; Merck with AWS and Accenture have published CSR authoring work; Yseop and Certara (CoAuthor) sell dedicated tools. Treat vendor-reported time savings as claims; none are quoted here as verified benchmarks.
• Why it is not generic report writing (LANG-003): numeric fidelity, per-sentence provenance and validated, audited processes are mandatory.

Variants

• Pharma CSR and protocol authoring: CSR bodies and appendices, protocol and amendment drafting, patient narratives, investigator brochure updates.
• CTD/eCTD module authoring: Module 2.5/2.7 clinical summaries, Module 3 quality text, label (SmPC) updates, eCTD packaging checks.
• Health-authority question responses: drafting answers to EMA/FDA deficiency lists from the existing dossier with cited evidence.
• EU CTR lay summaries: plain-language results summaries required under Regulation (EU) 536/2014, multi-language, reading-level checked.
• Periodic safety reports: PSUR/PBRER and DSUR drafting (data intake from HLTH-010).
• MDR/IVDR technical documentation: clinical evaluation reports (CER), performance evaluation reports, PMCF plans/reports, general safety and performance requirement (GSPR) mapping, summary of safety and clinical performance (SSCP).

How it works

1. source ingestion (TLFs, SAP, protocol, test reports, prior dossiers)
2. parsing + structuring (tables to typed data, section/ID anchors)
3. retrieval index per study/product (hybrid search, versioned)
4. section drafting (template + data-bound prompts; numbers inserted programmatically)
5. verification (every number matched to source cell; claim-to-source citation)
6. cross-document consistency check (protocol vs SAP vs CSR vs Module 2; CER vs risk file)
7. medical-writer review with tracked changes + audit trail
8. QC, approval (e-signature), publishing into eCTD / technical file

• Numeric fidelity: do not let the LLM type results. Fill values from the structured TLF data via placeholders, and let the model write only connecting prose; then run an automatic check that each number in the output exists in the source.
• Provenance: each sentence carries a link to table/listing/page; reviewers see the source beside the draft.
• Human-in-the-loop: writers own interpretation, benefit-risk statements and conclusions; statisticians confirm outputs; QA approves under the validated process.

Data preparation

Source material is the statistical output (TLFs, SAP, datasets), the protocol and amendments, prior submissions, templates and the risk management file. It typically lives in a clinical data repository, a validated eTMF or RIM system (e.g. Veeva Vault), SharePoint file shares and e-mail. Typical gaps: PDF-only tables and listings without machine-readable twins, scanned legacy reports, several document versions with unclear status, inconsistent terminology between studies, and narrow access rights per study and per blinded or unblinded role.

Preparation steps: inventory the sources per submission and pick the authoritative version of each (PREP-001, PREP-002); export tables as structured data from the statistics environment instead of parsing PDFs (PREP-005); OCR and convert legacy reports (PREP-006, DOC-014); build a glossary and terminology list per therapeutic area (PREP-015); collect approved gold-standard sections and templates (PREP-016); keep blinding and role permissions intact in the index (PREP-023). Tools: Docling or Azure Document Intelligence for parsing, a vector index with section-level metadata, and a source-ID scheme that makes every sentence traceable. Rough effort: about 30 to 40 percent of the project, mostly structuring tables and curating templates; the model work is the smaller part.

Implementation paths

Which path for whom

• Enterprise (B): Unpublished trial data and submission strategy are core trade secrets, and validated GxP pipelines need control over prompts, models and audit trails, so an EU-region API build with your own document and traceability layer fits better than a closed writing suite.
• Developer (C): Self-hosted open-weight models keep the full trial corpus in-house and let you build and validate the tooling you later ship to sponsors.

Path A — Buy (off-the-shelf)

• Dedicated tools: Yseop (France, EU), Certara CoAuthor, Veeva Vault RIM / Clinical (with AI features), Lorenz docuBridge and Extedo eCTDmanager for publishing (German, EU), IQVIA and other CRO offerings; for devices Greenlight Guru, MasterControl and Qualio/Scilife-type eQMS with AI assistance.
• Choose A when: GxP validation documentation, 21 CFR Part 11/Annex 11 controls and vendor audit packages are needed out of the box.

Path B — Build on cloud APIs

• Models: frontier LLMs (Claude, GPT, Gemini, Mistral) via enterprise agreements with zero data retention and EU regions (e.g. Amazon Bedrock Frankfurt, Azure OpenAI EU data zones, Vertex AI EU, Mistral in France).
• Stack: document parsing (Azure Document Intelligence, Mistral OCR), embeddings plus hybrid search, structured outputs, orchestration in a validated workflow engine, integration to Veeva Vault or a document management system.
• Choose B when: you have a platform team and want your own templates and checks; the Novo Nordisk and Merck/AWS examples follow this pattern.

Path C — Self-host (open source)

• Models: open-weight LLMs such as Llama, Qwen, Mistral and gpt-oss families via vLLM; domain models are less important than retrieval and verification quality.
• Parsing: Docling, MinerU; search with OpenSearch or pgvector; Langfuse or similar for tracing.
• Hardware: HW3 for ~70B-class models; HW4 for the largest open models. Choose C for unpublished data under strict confidentiality or for sovereign requirements.

Path D — Custom training

Fine-tuning on the sponsor's historic approved CSRs and style guides can improve tone and template adherence, but requires curated, rights-cleared documents and revalidation after each model change. Usually prompt libraries plus retrieval suffice.

State of the art (2026)

• Section-level drafting from structured data is in production at large sponsors; full end-to-end CSR generation is still reviewed line by line.
• Strong long-context reasoning models make cross-document consistency checking practical; deterministic number binding remains the key safeguard.
• Regulators engage actively: EMA published a reflection paper on AI in the medicinal product lifecycle and, with FDA, joint guiding principles on good AI practice in medicine development [1][2]. EMA also publishes guidance for its own staff's use of LLMs.
• Limits and failure modes: hallucinated or rounded statistics, silent change of populations or analysis sets, copying text from a prior study that does not apply, misquoted literature in CERs, loss of nuance in benefit-risk wording, inconsistent terminology across modules. Prompt-injection through source documents is a risk for ingested external literature.

Shared resources & combinations

• Shared stack: ocr-docparse, embedding/hybrid search and LLM drafting overlap with KNOW-002 (RAG), LANG-008 (summarisation) and LANG-022 (technical documentation).
• Upstream/downstream: HLTH-010 (safety data for PSUR/DSUR), HLTH-009 (trial design and protocol data), HLTH-029 (GMP records feeding Module 3), HLTH-028 (terminology coding such as MedDRA, SNOMED), HLTH-011 (clinical letters, different scope).
• One validated document-AI platform with shared audit trail can serve regulatory, quality and safety writing.

Effort, cost & KPIs

• A: weeks to pilot, months to validate and roll out; subscription or per-study licences.
• B: 4–9 months incl. validation (IQ/OQ/PQ-style evidence, intended-use specification); cost drivers are validation, integration and reviewer time rather than tokens.
• C: similar effort plus GPU operations.
• KPIs: time from database lock to first CSR draft, writer edit distance, number of factual errors found in QC per document, cross-document inconsistencies caught pre-submission, deficiency letters attributable to documentation errors, cost per submission.

People & change

Involve management early for budget and the AI policy, and the regulatory-affairs or medical-writing lead as process owner, who defines what counts as an acceptable draft. Bring in IT security and legal/compliance before any data leaves the validated environment (confidentiality, vendor audit, GxP validation), and data owners of the eTMF/RIM systems when exports are built. Medical writers and reviewers are the daily users and should shape the traceability and review workflow from the pilot onward.

Works council: depends. The system itself drafts documents rather than monitoring people, but usage logs and per-writer productivity metrics can be suited to monitor performance (§87(1) no. 6 BetrVG, objective suitability suffices according to the BAG), and §90(1) no. 3 requires timely information when work processes are planned with AI. If a works council exists, agree on a short works agreement that excludes individual performance evaluation. Personal data is mostly limited to trial participants in pseudonymised form; involve the DPO on narratives and safety reports, with a DPIA where patient-level data is processed (Art. 35 GDPR) and an AVV with every API provider.

AI literacy (Art. 4 AI Act, support measures only): train writers on hallucination risk, source checking and confidentiality. Start with a small pilot team on one document type, state clearly that the writer remains the author and signs off, and address fears of job loss by shifting time from assembling to reviewing. See GUIDE-008, GUIDE-006 and GUIDE-009.

Risks, regulation & compliance

• EU AI Act: typically minimal risk, as the system supports documentation rather than decisions about persons; AI literacy (Art. 4) applies. If the tool is part of, or becomes, a medical device function, high-risk rules may apply. Generated text sent to the public (lay summaries) should follow transparency expectations.
• GxP: computerised system validation (EU GMP Annex 11, draft Annex 22 on AI in GMP, ICH E6(R3) data governance), audit trails, change control for models and prompts. Accountability for content stays with the sponsor and named authors.
• GDPR: clinical data and narratives may be pseudonymised personal health data (Art. 9); use anonymised or pseudonymised inputs, DPA with providers, EU processing, no training on customer data.
• Confidentiality: unpublished dossier data is commercially critical; contractual zero-retention and access controls.
• Medtech: MDR requires the manufacturer to be responsible for technical documentation and CER; notified bodies expect traceable literature searches (MEDDEV 2.7/1 rev. 4, MDCG guidance) [3][4].
• Mitigations: programmatic number insertion, full source citation, dual review, red-team tests, locked model versions.

Getting started

1. Choose one section type (e.g. demographics and disposition text, or lay summaries) with clean structured inputs.
2. Define intended use, risk assessment and acceptance criteria with QA before building.
3. Build or buy with source-linked drafting and automatic number verification; test on 5–10 completed historical studies and compare to the approved text.
4. Run a writer-review pilot, measure edit effort and errors found, then extend to further sections and cross-document checks.
5. Document validation and training, and agree the use with the notified body or regulatory affairs where relevant.

Sources

1. EMA — Reflection paper on the use of AI in the medicinal product lifecycle — https://www.ema.europa.eu/en/use-artificial-intelligence-ai-medicinal-product-lifecycle-scientific-guideline
2. EMA — EMA and FDA set common principles for AI in medicine development — https://www.ema.europa.eu/en/news/ema-fda-set-common-principles-ai-medicine-development-0
3. Regulation (EU) 2017/745 (MDR) — https://eur-lex.europa.eu/eli/reg/2017/745/oj
4. Regulation (EU) No 536/2014 (Clinical Trials Regulation) — https://eur-lex.europa.eu/eli/reg/2014/536/oj
5. ICH E3 Structure and content of clinical study reports — https://www.ich.org/page/efficacy-guidelines
6. Regulation (EU) 2024/1689 (AI Act) — https://eur-lex.europa.eu/eli/reg/2024/1689/oj
7. Yseop — https://www.yseop.com
8. Certara CoAuthor — https://www.certara.com/software/coauthor/
9. Anthropic customer story, Novo Nordisk — https://www.anthropic.com/customers/novo-nordisk
10. Anthropic — Novo Nordisk accelerates clinical documentation with Claude (NovoScribe; customer story) — https://claude.com/customers/novo-nordisk